December 15, 2017 3:41 PM ET

Biotechnology

Company Overview of Ab Initio Biotherapeutics, Inc.

Key Executives for Ab Initio Biotherapeutics, Inc.

NameBoard RelationshipsTitleAge
Kenneth S. Lin M.D.2 RelationshipsCo-Founder, Chief Executive Officer and President --
John Burg Ph.D.No RelationshipsHead of Biochemistry--
Roy Maute Ph.D.No RelationshipsHead of Biology--

Ab Initio Biotherapeutics, Inc. Board Members*

NameBoard RelationshipsPrimary CompanyAge
Timothy A. Springer Ph.D. 64 RelationshipsMorphic Rock Therapeutic, Inc.69
Brian K. Kobilka M.D. 5 RelationshipsConfometRx, Inc.--
Robert F. G. Booth Ph.D. 45 RelationshipsVirobay Inc.63
Aaron Ring M.D., Ph.D. 5 RelationshipsAb Initio Biotherapeutics, Inc.--
Andrew Kruse Ph.D. 5 RelationshipsAb Initio Biotherapeutics, Inc.--
View All Board Members

Ab Initio Biotherapeutics, Inc. Executive Committees*

Committee NameChairpersonBoard RelationshipsMembers
There is no committee data available.
*Data is at least as current as the most recent Definitive Proxy.
\
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

CEO COMPENSATION IN THIS INDUSTRY

  Industry Range
Salary
386.9K
Bonus
237.8K
Total Short Term Compensation
482.5K
Total Value of Options
18.1M
Compensation as of Fiscal Year
Ab Initio Biotherapeutics, Inc. CEO Compensation
Industry Average

INDUSTRY EXECUTIVE CHANGES

Peregrine Pharmaceuticals, Inc. Appoints Roger J. Lias, Ph.D. as Principal Executive Officer
December 14, 2017 10:00 PM ET
Gilead Sciences Announces That John C. Martin, Will Transition from Executive Chairman to Chairman of the Board of Directors, Effective March 9, 2018
December 14, 2017 9:30 PM ET
Esperion Announces the Appointment of Jeffrey Berkowitz to Board of Directors
December 14, 2017 9:30 PM ET
Cellect Biotechnology Ltd. Announces Executive Changes
December 14, 2017 9:30 PM ET
Sangamo Therapeutics, Inc. Announces Resignation of William R. Ringo from the Board Effective January 1, 2018
December 14, 2017 9:16 PM ET

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Ab Initio Biotherapeutics, Inc., please visit . Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.